Clincosm LogoSign in Get a demo

Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance Following Keloid Scar Revision Surgery

Sponsor
Golla Center for Plastic Surgery (Other)
Overall Status
Unknown status
CT.gov ID
NCT02521402
Collaborator
(none)
10
Enrollment
1
Location
1
Arm
22
Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main purpose of this study is to see if there is clinical benefit of using Biovance in reduction of the recurrence of keloids when used to revise them. It will also assess the postoperative complications.

Condition or Disease Intervention/Treatment Phase
  • Biological: Biovance
 Phase 4

Detailed Description

To assess the performance of Biovance, patients will consulted regarding the history and previous treatment of their keloid. Once patients are deemed to be appropriate candidates, they will be enrolled in the study. Operatively, the old scar will be completely excised. Then the Biovance will be laid in the base of the wound. After this is performed, extensive undermining will be done to close the wound in layers.

All post-revision complications (including infection, incision dehiscence, hematoma, seroma, and wound necrosis) will be assessed and recorded by the investigator. Patients will be reviewed to obtain demographic and risk factor (such as age, body mass index, smoking) data. Data on adjuvant therapy use (previous surgeries, treatments for keloid scar) will be collected. Surgical technique details (such as incision size and closure technique) will also be recorded for each patient. Photographs documenting the pre-, intra- and post-revision clinical course of patients will be collected.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery
Study Start Date :
Aug 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Jun 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Other: Keloid Revision Surgery with Biovance

All enrolled patients will have Biovance applied during Keloid Revision Surgery

Biological: Biovance
decellularized, dehydrated human amniotic membrane

Outcome Measures

Primary Outcome Measures

  1. Incidence of keloid scar recurrence after revision surgery with placement of Biovance [1 year post-surgery]

    Published data in the literature reporting on keloid scar incidence and recurrence without the use of Biovance may serve as a reference/historical control.

Secondary Outcome Measures

  1. Clinical outcomes of keloid scar revision surgery, including scar size and appearance [1 year post-surgery]

  2. Incidence of complications (including infection, incision dehiscence, hematoma, seroma, and wound necrosis following revision surgery [1 year post-surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
The subject has:

  1. been diagnosed with a keloid scar

  2. a keloid scar that is located on the face, neck, arm, trunk, or groin area

  3. is between the ages of 21 and 80 years old

  4. competency as an adult, per applicable state law who is willing to provide written informed consent

  5. the intent and ability to return for all scheduled and required visits and follow recommended standard post surgical treatment for keloid scar excision.

Exclusion Criteria:
The subject has:

  1. clinical evidence of infection of the keloid scar

  2. any malignancy or a neoplasm at the keloid scar site

  3. any significant comorbid disease that may interfere with wound healing, known active Hepatitis A, B, or C or Acquired Immune Deficiency Syndrome or is known to be infected with HIV, a known collagen disorder or autoimmune disease [including systemic lupus erythematosis (SLE), rheumatoid arthritis (RA),fibromyalgia, polymyositis, scleroderma, ankylosing spondylitis, dermatomyositis, osteogenesis imperfecta or the inherited disorders of Sjogren, Larsen, Raynaud, Ehlers-Danlos or Marfan syndrome]

  4. received chemotherapy, radiotherapy, immunosuppressives or corticosteroids (greater than 10 mg prednisone-equivalent per day) within the past 30 days.

  5. a known history of abuse of alcohol or drugs (prescribed or illegal), significant psychiatric personality or psychotic disorder requiring chronic psychotropic therapy, or gross noncompliance to recommended therapies

  6. condition(s) that would adversely affect subject safety by following the protocol

  7. any contraindication for use of Biovance

Contacts and Locations

Locations

Site City State Country Postal Code
1 Golla Center for Plastic Surgery Pittsburgh Pennsylvania United States 15236

Sponsors and Collaborators

  • Golla Center for Plastic Surgery

Investigators

  • Principal Investigator: Dinakar Golla, MD, Golla Center for Plastic Surgery

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Golla Center for Plastic Surgery
ClinicalTrials.gov Identifier:
NCT02521402
Other Study ID Numbers:
  • Golla-01-Keloid
First Posted:
Aug 13, 2015
Last Update Posted:
Aug 13, 2015
Last Verified:
Aug 1, 2015
Additional relevant MeSH terms:
Keloid

Study Results

No Results Posted as of Aug 13, 2015